Medical device companies have announced their first quarterly reports, and many companies' net profit has risen sharply

With the continuous development of the economic level and the increasing demand for health, China's medical device market is ushering in a huge development opportunity
.
According to data, from 2014 to 2020, China's medical device market has achieved a growth of 500 billion yuan
.
In terms of growth rate, the average annual growth rate of China's medical device market is maintained at about 20%, exceeding the growth rate of the global market by about 5%
.
Due to the continuous improvement of the domestic medical device market, the performance and net profit of a large number of enterprises are also increasing continuously
.
On April 20, Mindray Medical released its 2021 annual performance report and its first quarter 2022 financial report
.
Data shows that in 2021, Mindray Medical's revenue will be 25.
27 billion yuan, a year-on-year increase of 20.
18%; the net profit attributable to shareholders of listed companies is 8 billion yuan, a year-on-year increase of 20.
19%
.
In the first quarter of 2022, Mindray Medical's revenue and net profit growth rate exceeded 20%, with revenue of 6.
94 billion yuan, a year-on-year increase of 20.
1%; attributable net profit of 2.
1 billion yuan, a year-on-year increase of 22.
74%
.
After the performance report was released, investment institutions flocked.
Wind data shows that more than 550 institutions have conducted research on Mindray Medical in the past week, including 113 public funds, 21 insurance funds, 72 securities companies and 219 investment institutions.

.
Wantai Bio is an enterprise engaged in the research, development, production and sales of in vitro diagnostic reagents, instruments and vaccines
.
The 2021 annual report shows that the company achieved revenue of 5.
75 billion yuan, a year-on-year increase of 144.
25%; net profit attributable to the parent was 2.
021 billion yuan, a year-on-year increase of nearly 200%
.
In the first quarter, Wantai Bio's performance continued to develop well, with operating income, net profit attributable to the parent and net profit after deduction of non-deductibles of 3.
171 billion yuan, 1.
331 billion yuan and 1.
315 billion yuan, up 284.
85% and 360.
18% year-on-year respectively.
and 367.
75%, achieving earnings per share of 2.
19 yuan, exceeding market expectations
.
For the growth in performance, Wantai Bio said that it was mainly due to the increase in revenue from bivalent cervical cancer vaccines, reagents and active raw materials, as well as the substantial increase in overseas testing demand, and the rapid growth in the company's raw material sales and overseas testing reagent export revenue
.
Yirui Technology's performance in 2021 and the first quarter of 2022 also increased significantly.
Its operating income was 1.
187 billion yuan, a year-on-year increase of 51.
43%; net profit attributable to the parent was 484 million yuan, a year-on-year increase of 117.
79%; basic earnings per share was 6.
67 yuan
.
In the first quarter of 2022, Yirui Technology's performance continued to grow at a high rate, and the revenue and profit sides were in line with expectations
.
According to the data, Yirui Technology is a digital X-ray detector manufacturer oriented by the technology development trend of the whole industry chain and its technical level is in line with international standards.
It is mainly engaged in the research and development, production, sales and service of digital X-ray detectors, and its products are widely used.
In the fields of medical diagnosis and treatment, industrial non-destructive testing, safety inspection,
etc.
In addition, Shengxiang Biological also performed well
.
On April 19, Shengxiang Bio released its 2021 annual report and 2022 first quarter report
.
The annual report shows that Shengxiang Bio will achieve revenue of 4.
515 billion yuan and net profit of 2.
24 billion yuan in 2021.
It plans to distribute cash dividends of 3.
75 yuan (tax included) to all shareholders for every 10 shares, with a total cash dividend of 148 million yuan (tax included)
.
The first quarterly report shows that Shengxiang Bio achieved revenue of 1.
44 billion yuan in the first quarter of 2022, a year-on-year increase of 23.
81%; net profit of 652 million yuan, a year-on-year increase of 4.
78%; net cash flow from operating activities was 551 million yuan, a year-on-year increase.
79.
37%
.
In general, the medical device market has broad prospects.
As the market continues to develop, the performance of related companies has also ushered in substantial growth
.
However, in recent years, in order to strengthen the supervision and management of medical device production and standardize the development of the medical device industry, some new policies and new regulations issued by relevant departments are making the medical device industry usher in stricter supervision.
It will be more likely to meet challenges and embrace more new market opportunities
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.